BIOMARCATORI 1
19
1
Prolonged low-rate nerve stimulation during regional ischemia: a potential neurophysiological biomarker in McArdle disease
2
Systematic assessment of square wave jerks in progressive supranuclear palsy: a video-oculographic study
3
Longitudinal changes in cerebrospinal fluid alpha-synuclein RT-QuIC outcomes during the preclinical to clinical stages of neuronal synuclein disease
4
A real-life study to assess K-index diagnostic and prognostic role in early phases of Multiple Sclerosis (MS)
5
Cerebrospinal fluid NPTX2 and metabolic correlates of delayed recall in MCI-AD: insights from FDG-PET voxel-wise analysis
6
Visinin-like protein-1 in cerebrospinal fluid as a biomarker of neuronal damage in dementia and mild cognitive impairment due to Alzheimer Disease: a cross-sectional study
7
Rituximab in refractory myasthenia gravis: 5 year single center follow up
8
Assessment of cardiovascular risk factors and impact on prognosis in multiple sclerosis: a single center experience
9
Oral curcumin for Alzheimer's disease: impact on CSF neurochemical profile
10
Correlation between markers of dysregulated mitochondrial dynamics and synaptic dysfunction in patients with Alzheimer Disease
11
Pupillary light reflex in the early stages of alpha-synucleinopathies
12
Assessment of neurodegeneration markers in olfactory neurons of patients with post-Covid 19 olfactory dysfunction
13
Kidney function and Alzheimer's disease: impact on plasma biomarkers and correction factors
14
The identification of prodromal Dementia with Lewy Bodies by skin biopsy among patients with recent-onset dementia
15
Determinants driving evolution of newly formed MS lesion into chronic active, chronic demyelinated and remyelinated lesions
16
Neurofilament light chain as clinical plasma biomarker of Charcot-Marie-Tooth disease
17
Understanding the interplay between multiple sclerosis patterns and ovarian reserve
18
Sex-Related Differences in Inflammatory Pathways in Schizophrenia Spectrum Disorders
19
Serum miRNA signature in neurofibromatosis type 1: emerging biomarkers and clinical implications
BIOMARCATORI 2
19
340
Role of specific microRNAs in cluster headache: correlation with disease phenotype and neuropeptide levels
341
Stage-dependent phosphoproteomic profile of Parkinson's disease peripheral immune cells
342
Does cerebrospinal fluid neurofilament light chain correlate with psychiatric symptoms severity in multiple sclerosis?
343
Oculomotor features in SCA27B patients
344
Biomarkers of Neurodegeneration in iNPH, LOVA, and other neurodegenerative diseases: a pilot study.
345
Gastrointestinal dysfunction accounts for a specific clinical-biological profile in Parkinson's disease
346
Microbiota-derived metabolome: towards a non-invasive biomarker of multiple sclerosis
347
Linking Mitochondrial Dysfunction with Glial and Neuroaxonal degeneration in Creutzfeldt-Jakob Disease
348
Control of core temperature in major orthopedic surgery and traumatology in old patinets with delirium using donepezil
349
Control of core temperature in major orthopedic surgery and traumatology in old patinets with delirium and valutation Mini Mental test.
350
Plasma pTAU levels can distinguish cognitively unimpaired patients with PD from patients with HC and patients with PDD, DLB and AD.
352
Ofatumumab Reduces Clinical and Radiological Activity in People with Recently Diagnosed Treatment-naive Relapsing Multiple Sclerosis Irrespective of Baseline Serum Neurofilament Light Chain Levels
353
Prognostic Value of Serum Neurofilament Light Chain for Disease Activity in Patients With Relapsing Multiple Sclerosis: Results From Subgroup Analysis Based on Body Mass Index and Age from the Phase 3 ASCLEPIOS I/II Trials
354
Prognostic Value of On-Treatment Serum Neurofilament Light Chain for New or Enlarging T2 Lesions in People With Relapsing Multiple Sclerosis: Pooled Analysis of the ASCLEPIOS I/II Trials
355
CSF and amyloid PET concordance in amyloid pathology detection: a comparison of the two methods
356
Blood-Brain Barrier alterations as possible biomarkers of Depressive symptoms in Alzheimer's Dementia Patients
357
The relationship between Synaptic dysfunction and Neuronal, Glial and Inflammatory alterations in Alzheimer's disease
358
Establishment of normal reference values for serum neurofilament light based on apparently healthy subjects aged 18Cb,b 90 years."
359
Performance and concordance of plasma versus CSF biomarkers of Alzheimer's Disease: a single center Memory Clinic cohort"
BIOMARCATORI 3
19
675
Baseline Serum Neurofilament Light Chain Levels Predict Future Disease Activity Irrespective of Race/Ethnicity: Results From the Phase 3 ASCLEPIOS I/II Trials
676
Role of blood p-tau isoforms (181, 217, 231) in predicting the progression from MCI to dementia due to Alzheimer's disease: a review and metanalysis
677
Patients affected by Alzheimer's disease with different Rate of Progression showed differences in CSF biomarkers related to Neurodegeneration and Synaptic disfunction: a preliminary study."
678
Blood-based biomarkers of oxidative stress to predict post-operative cognitive impairment in patients undergoing coronary artery bypass grafting
679
Cerebrospinal fluid interleukin-6 as a potential biomarker in CNS neuroinflammatory diseases: a real world analysis.
680
Real-world performance of serum biomarkers for the detection of amyloid brain pathology
681
Neurofilament Light Chain and AlzheimerCb,b"s Pathology in Elderly Patients with Multiple Sclerosis"
682
Neuronal and glial biomarkers in a cohort affected by Lewy Body Dementia with and without GBA1 mutations: a multicentric deep-phenotyping biological study
683
Adding mindfulness practice to treatment as usual in patients with CM-MOH: an analysis of inflammatory pattern
684
Plasmatic ACB242/40 ratio and p-tau181 in A+/T+ patients: diagnostic performance in a real-world setting
685
Correlations between CSF biomarkers of AlzheimerCb,b"s disease and neuropsychological tests in a cohort of Parkinson disease patients"
686
Circulating X chromosome inactivation and Xist from a cohort of female carriers of Fabry Disease
687
Preliminary analysis of Tissue Transglutaminase 2 expression in peripheral blood mononuclear cells in patients with Radiologically Isolated Syndrome
688
Impact of Augmentative Alternative Communication on Healthcare Providers satisfaction: Enhancing Communication with Aphasic Patients.
689
THE POTENTIAL ROLE OF ALFA-2 MACROGLOBULINE AND S100B PROTEIN AS A PREDICTORS OF FUNCTIONAL OUTCOME IN STROKE PATIENTS. PRELIMINARY RESULTS FROM THE NIMBLE STUDY.
690
Beware of the tick! A case of Borrelia-induced CNS vasculitis presenting with recurrent posterior circulation strokes
691
When the heart speaks first: a 30 years history of pseudo-drug resistant epilepsy.
692
SOD1-ALS PATIENTS IN TOFERSEN: LONGITUDINAL EVALUATION OF CLINICAL AND BIOLOGICAL VARIABLES
694
Diagnostiàiomarkers in patients with mild traumatiàrain injury. BIO-BRAIN: rationale and study design.
brain health e prevenzione/ neurologia digitale/ neuroepidemiologia
13
929
Heat Stress and Neurological Damage: Analysis of Neuro-Glial Damage Biomarkers
930
Enhancing Cognitive and Brain Reserve: Exploring the Impact of Foreign Language Learning on the Aging Brain
931
Assessment of Nutritional Status in patients with Cognitive Impairment: a pilot study
932
AN OVERALL PICTURE OF OUTPATIENTS NEUROLOGY SERVICES IN THE LATIUM REGION, ITALY
933
A multicenter study in Sicily, Southern Italy on immune mediated syndromes associated to onconeural antibodies
934
Visual Pareidolia in non-demented patients of a Stroke Unit
935
Clinical evolution and survival of chronic patients with Disorders of Consciousness: a retrospective study
936
Guillain-BarrCB) Syndrome during the COVID-19 pandemic in Italy: self-controlled case series- SCOVANE study
938
The EU project "STRATIF-AIC"
939
The Lombardia Region PERLA project: towards a new diagnostic and therapeutic pathway for patients with chronic headache disorders
940
Feasibility and effectiveness of a mindfulness program delivered by web to patients during hospitalization and caregivers: a pilot study (The KIMPO Project)
941
Cooperation protocol for social and health care integration in Milan area. Districts 7-6-5 experience.
942
Wellbeing at the work place and behind: Feasibility and effectiveness of a mindfulness program delivered by web to nurses in an Italian neurological department: a pilot study
CEFALEE E DOLORE 1
22
20
Influence of triptans use on anti-CGRP mAbs response: a prospective cohort study
21
Gender differences in the expression of central sensitization symptoms in migraine: an observational study in a tertiary headache center
22
ENDOVASCULAR VENOUS SINUS STENTING: A VALID THERAPEUTIC OPTION IN REFRACTORY IDIOPHATIC INTRACRANIAL HYPERTENSION.
23
Molecular-enriched functional connectivity fingerprint of the serotonin system in medication overuse headache patients
24
COMPARISON OF EFFECTIVENESS AND SAFETY OF MONOCLONAL ANTIBODIES TARGETING CGRP FOR MIGRAINE PREVENTION AND AGE-RELATED SUB-GROUPS ANALYSIS: A 12-MONTHS, MULTICENTER, PROSPECTIVE, REAL-LIFE STUDY
25
LOST IN TRANSITION: FACTORS ASSOCIATED WITH EFFECTIVE TRANSITION FROM PEDIATRIC TO ADULT HEADACHE CARE
27
Efficacy of galcanezumab in PRRT2-associated Familial Hemiplegic Migraine: a case series.
28
Unveiling the demographic, social, and clinical characteristics of migraine in Italy: Insights from the Nationwide, Prospective, Italian Migraine Registry (I-GRAINE)
29
Gut microbiota ecosystem in pediatric migraine. How are dysbiosis, inflammation and intestinal metabolites involved?
30
A head to head cohort study on the effiacy and safety of Indomethacin and Ibuprofen for the acute treatment of migraine
31
Early effect of OnabotulinumtoxinA on EEG-based functional connectivity in patients with chronic migraine
32
Multi-parametric efficacy assessment of Eptinezumab in patients with chronic migraine and medication overuse headache: early results from a third level headache center.
33
High prevalence of fatigue in migraine patients in comparison with other chronic neurological diseases
34
Functional connectivity alterations in medication overuse headache
35
ANALYSIS OF FACTORS INFLUENCING THE MONOCLONAL ANTIBODIES AGAINST CGRP PRESCRIPTION IN A COHORT OF VERY YOUNG ADULTS WITH MIGRAINE.
38
Exploring Atypical Spontaneous Intracranial Hypotension: a case of Myasthenia Gravis with Brain Sagging
39
Brain resting state networks in episodic cluster headache: cerebral connectivity analysis with HD-EEG
40
Sustained Response to Atogepant in Individuals With Episodic Migraine and Prior Inadequate Response to Preventive Treatment and in Individuals With Chronic Migraine: Post hoc analyses From ELEVATE and PROGRESS
41
Real-world Switching Rates of Atogepant Are Lower Than CGRP Monoclonal Antibodies (mAbs) in Patients With Migraine Using Claims Database
42
Inflammatory profile and monocytes differentiation in migraine: association with disease severity
43
Restarting migraine preventive treatment with CGRP antibodies after drug holiday: Insights from the Mondino Tertiary Care Center real-world experience
44
Exploring Gender Disparities in the Effects of Long-Term Botulinum Toxin A Treatment for Chronic Migraine
CEFALEE E DOLORE 2
22
360
In a population of young stroke patients, the characteristics of migraine with aura can predict the likelihood that the stroke is related to the presence of a PFO?
361
Impact of Atogepant on Patient Functioning Among Participants With Episodic Migraine: Migraine-Specific Quality of Life Questionnaire v2.1 Item-Level Analysis
362
REVERSIBLE CEREBRAL VASOCONSTRICTION SYNDROME: A RARE CAUSE OF MIGRAINE WITH AURA
363
Evaluation of Crystal-Clear Days in Migraine Patients Receiving CGRP Monoclonal Antibodies
364
Is there still a place for detoxification strategies in migraine therapeutic scenario?
365
Head-to-head observational cohort study on the effectiveness and tolerability of subcutaneous monoclonal antibodies acting on CGRP pathway in patients with high frequency episodic migraine and chronic migraine
366
Morphometric Similarity Networks in paediatric migraine without aura: unravelling the role of gender
367
Alexithymia increases the risk of chronification in women with migraine; preliminary results
368
Recurrence of migraine after discontinuation of Anti-CGRP monoclonal antibodies: predictive clinical factors
369
Daily and night functioning improvement in pharmacoresistant migraine patients just after 6 months treatment with Anti CGRP/R mAbs
370
Bipolar spectrum disorders and cyclothymia are associated with Medication overuse
371
COVID 19 RELATED HEADACHE AND LONG COVID HEADACHE: SINGLE CENTER EXPERIENCE
372
Effectiveness and safety of using anti-CGRP monoclonal antibodies in migraine patients with a comorbidity disorder
373
Cervical meningioma underlying facial episodic paresthesia, tinnitus and vertigo
374
Effect of anti-CGRP monoclonal antibodies on anxiety and mood disorders in migraineurs
375
Evaluation of Eptinezumab effectiveness and tolerability: real life single-centre experience
376
Evaluation of migraine related cognitive symptoms in patients with high frequency episodic and chronic migraine
377
Advancing Globally Neurological Education in the Headache Field
378
IS THE 15-DAY THRESHOLD IN THE DEFINITION OF MIGRAINE WORSENING ASSOCIATED TO MEDICATION OVERUSE REASONABLE?
379
Results from the 2nd Italian interim analysis of the PEARL study: participants' quality of life over 12 months with fremanezumab treatment
382
Beyond Idiopathic Intracranial Hypertension: A Case of Hidden Dural Arteriovenous Fistula
383
A STRANGE CASE OF HEADACHE IN THE ELDERLY
CEFALEE E DOLORE 3
20
695
Eptinezumab treatment in patients with previous anti-CGRP (R) monoclonal antibodies therapy: a retrospective study of real-world clinical evidence of efficacy
696
A series of unfortunate events: two rare neurological complications of a rare tumor at carotid bifurcation
697
ANCA-associated hypertrophic pachymeningitis: a rare cause of headache and progressive cranial neuropathies
698
Hemiplegic migraine as presenting symptom of Evans syndrome: a case report
699
Recurrent painful ophthalmoplegic neuropathy: a high frequency case with adulthood onset.
700
RECURRENT DIPLOPIA AS ISOLATED SYMPTOM OF ATYPICAL SPONTANEOUS INTRACRANIAL HYPOTENSION
701
An Unusual Presentation of Giant Cell Arteritis
702
A Case of Glossopharyngeal Neuralgia Successfully Treated with Amitriptyline and Gabapentin
703
Anti-CGRP mAbs in a 92-year-old patient: A CASE REPORT
704
Acute Unilateral Sixth Cranial Nerve Palsy and Headache as Initial Manifestations of Carcinomatous Meningitis
707
An unusual occipital-temporal headache in a 17 years old boy: the value of somatosensory evoked potentials (SSEP)
708
Persistent Idiopathic Facial Pain. A challenging diagnostic entity: clinical experience from a Neuroalgology Department
709
Cognitive and Mood Evaluation in Trigeminal Neuralgia Patients Pre- and Post-Gamma Knife Treatment
710
Dr. Rita Formisano
711
Vascular Compression in Trigeminal Neuralgia Discloses Trigeminal Root Somatotopic Organization
712
Diagnostic accuracy of quantitative sensory testing for the diagnosis of small fibre neuropathy
715
Gender disparities in response to treatment with subcutaneous injections of Botulinum toxin type A in chronic neuropathic pain.
716
Gabapentinoids use and abuse in Neuropathic Pain Unit
717
Presenting a protocol for using abobotulinumtoxinA to treat neuropathic pain in carpal tunnel syndrome: A multicenter, randomized, double-Blind, placebo-controlled Study (INjECT Study).
718
Long-Term Safety, Tolerability, and Efficacy of Atogepant for the Preventive Treatment of Migraine: Interim Analysis of a Phase 3, Multicenter, Open-Label, 156-Week Long-Term Safety Extension Study
DEMENZA E INVECCHIAMENTO 1
23
85
Discriminative Accuracy of Plasma pTau-217 Assessed by Automated Lumipulse G600II Across CSF Biomarker Profiles in AlzheimerCb,b"s Disease"
86
Peripapillary retinal nerve fiber layer thickness in MCI and dementia
87
Risk of dysphagia in primary progressive aphasia: demographic, clinical, behavioural and neuroanatomical features
88
Sentence comprehension deficits in Italian and English nfvPPA: A cross-linguistic perspective.
89
An Italian scale for the assessment of motor speech disorders in patients with neurodegenerative diseases
90
Amy-PET features of regional amyloid deposition and hypoperfusion in probable CAA: a preliminary study
91
Neuropsychological tests as predictors of amyloid-PET status in a heterogeneous cohort of MCI and mild dementia patients
92
Gender differences in Cognitive Reserve in Subjective Cognitive Decline: a problem of belonging generation?
93
Brain functional connectivity changes and cortical neurotransmitter receptor distribution associated with psychotic symptoms in AlzheimerCb,b"s disease "
95
Brain hypometabolism and errors on the Clock Drawing Test predict conversion from Mild Cognitive Impairment to Alzheimer's dementia"
96
The role of neuroinflammation in Alzheime's disease: A systematic literature review."
97
Optimizing Early Detection of Cognitive Impairment: Evaluating Toolkits for Screening First-Time SCD Patients
99
Effects of lamotrigine to reduce emotional lability in AlzheimerCb,b"s disease and vascular dementia"
100
Baseline characteristics from evoke and evoke+: Two phase 3 randomized placebo-controlled trials of oral semaglutide in patients with early Alzheimer's disease.
101
Anti-amyloid monoclonal antibodies and ARIA in Early AD: A case series with favorable outcomes
102
Informal and Formal Settings in Neuropsychological Evaluation in Moderate-Severe AlzheimerCb,b"s Disease"
103
Plasma phospho-Tau 181 as a predictor of emergency department use in cognitively impaired patients: preliminary results from an ongoing longitudinal study.
104
Normal pressure hydrocephalus does not matter: an Italian perspective
105
Prevalence of idiopathic normal pressure hydrocephalus in patients with fractures
106
Idiopathic Normal Pressure Hydrocephalus: A Critical Analysis of Its Underrepresentation Across Italian Medical-scientific Societies in the last 5 years
107
Control of core temperature in major orthopedic surgery and traumatology in old patinets with delirium
108
Control of core temperature in major orthopedic surgery and traumatology in old patinets with delirium and valutation of pressure sores
109
Control of core temperature in major orthopedic surgery and traumatology in old patinets
DEMENZA E INVECCHIAMENTO 2
21
447
In 2024 iNPH is still a social and economic burden
448
Associations between Biomarkers of Amyloidopathy, Tauopathy, Neurodegeneration and Inflammation and Blood-Brain Barrier Dysfunction in Mild Cognitive Impairment due to Alzheimer's Disease
449
Young-onset dementia in Padova County: epidemiological and care-pathway study
451
The relationship between blood-based protein biomarkers and brain MRI in the Alzheimer's disease continuum: A systematic review"
453
Serum Neurofilaments as diagnostic biomarkers in late-onset frontal lobe syndrome: role in the differential diagnosis of FTD versus primary psychiatric diseases
454
Is there a causative role of intermediate C9orf72 expansion in frontotemporal dementia? A case series.
455
Evaluation of participant characteristics in clinical trials investigating amyloid- and tau-targeting monoclonal antibodies for Alzheimer's disease: a systematic review"
457
Combined intake of red wine and mocha coffee on cognition and mood in elderly patients with mild vascular cognitive impairment
458
Cerebrospinal fluid/serum albumin ratio (Q-Alb) in frontotemporal lobar degeneration syndromes
459
Validation and Convergent Validity of the Boston Cognitive Assessment (BOCA) in an Italian Population: A Comparative Study with the Montreal Cognitive Assessment (MoCA) in Alzheimer's Disease Spectrum.
460
The impact of comorbidities on dementia conversion: a principal component and cluster analysis
461
KOKEDAMA: A NEW JAPANESE GARDENING TECHNIQUE FOR ALZHEIMER DISEASE AND DEMENTIA
462
At the crossroads between Frontotemporal Dementia and AlzheimerCb,b"s Disease: a case report"
463
Atypical presentations of Lewy bodies disease misdiagnosed with limbic encephalitis or epileptic seizures: a case series with EEG and FDG-PET/MRI findings
464
Inflammatory cerebral amyloid angiopathy with focal leptomeningeal involvement: multimodal imaging findings
465
Epidemiological study on potential protective factors for dementia in a small Italian village
466
Acute neuropsychiatric deficits with hypermetabolism of the bilateral amygdala: the dilemma between autoimmune encephalitis and Lewy body disease.
467
Familial Creutzfeldt-Jakob disease. Description of a new case.
468
Acute Wernicke's encephalopathy mimicking stroke in esophageal cancer receving chemioterapy
469
Aspecific visual field defects as the first presentation of dementia: a case of posterior cortical atrophy
470
Frontal variant of AlzheimerCb,b"s disease: a challenging diagnosis"
DISORDINI DEL MOVIMENTO 1
21
252
A new wearable device based on inertial sensors to predict the DAT-SPECT result in patients with rest tremor: implications for routine clinical practice
253
Acute and long-term effects of Deep Brain Stimulation on cortico-cortical functional connectivity in ParkinsonCb,b"s disease: a high-density EEG study"
255
Brain hypometabolism and clinical features of GBA individuals
256
Conventional investigations in patients with Functional Motor Disorders
257
GLP-1 receptor agonist: a new disease-modifying therapy in Parkinson's disease? A systematic review and meta-analysis
258
Longitudinal assessment of blepharospasm severity in patients with long disease duration
259
Characterization of lower urinary tract symptoms in Parkinson's disease Clinical Subtypes
260
Analysing the bradykinesia features combination in people with ParkinsonCb,b"s disease and elderly healthy individuals"
261
Disentangling Bradykinesia and Rigidity in Parkinson's Disease: Evidence from Short- and Long-Term Subthalamic Nucleus Deep Brain Stimulation
262
Periodic Leg Movements during Sleep Associated with REM Sleep Behavior Disorder: A Machine Learning Study
263
Comparison of tolerability and efficacy of different add-on therapies in fluctuating Parkinson's disease patients
264
Reliability of neurophysiological and cerebral tremor features in Parkinson's disease
265
Retinal alterations in patients with ParkinsonCb,b"s Disease and visual hallucinations."
266
Magnetic Resonance-guided Focused Ultrasound (MRgFUS) in patients with ParkinsonCb,b"s disease: motor effects beyond tremor "
267
Genotype-phenotype correlation in a genetic ParkinsonCb,b"s disease cohort: analysis of a single center experience"
268
Botulinum toxin modulates the thalamocortical network in patients with cervical dystonia
269
Movement disorders after basal ganglia ischemic lesions following mechanical thrombectomy: an emerging clinical entity.
273
The influence of sex hormones on EEG-based functional connectivity in early-stage ParkinsonCb,b"s disease patients "
274
Rigidity in ParkinsonCb,b"s disease: the effect of L-dopa and activation maneuver on viscoelastic components"
275
Risk assessment is selectively biased by dopaminergic drugs in impulsive-compulsive parkinsonian patients
276
Diagnostic outcomes of Acute/Subacute Chorea: a retrospective analysis with a systematic literature review
DISORDINI DEL MOVIMENTO 2
23
277
Primary endpoints in randomized controlled trials evaluating Deep Brain Stimulation in Parkinson's disease
278
Investigating the effects of anodal transcranial direct current stimulation on the primary motor cortex in multiple system atrophy: a small pilot study.
280
Real-world experience of the safety of magnetic resonance imagingCb,b guided focused ultrasound (MRgFUS)-thalamotomy for essential tremor"
282
Phenotypic comparison between Combined Dystonia Parkinsonism and Isolated Idiopathic Dystonia
283
Investigating cerebral network changes in cervical dystonia using transcranial magnetic stimulation and electroencephalography
284
Continuous gait monitoring of Parkinson's disease patients during STN DBS under chronic sensing: a pilot study"
285
L-Dopa/Carbidopa Intestinal Gel in Advanced Parkinson's Disease: Long-term Monitoring through Wearable Sensors "
286
Safinamide introduction in ParkinsonCb,b"s Disease: a potential to spare antiparkinsonian therapy over time"
287
Physical activity and neurotrophic factors as potential drivers of neuroplasticity in ParkinsonCb,b"s Disease: A systematic review and meta-analysis."
288
Effects of GBA mutations in patients with Parkinson's disease and Levodopa-carbidopa intestinal gel: a nation-wide multicentre study
289
Motor and nonmotor functional connectivity predicts treatmentCb,brelated motor complications in early ParkinsonC"b,b"s disease patients"
290
Testing Machine Learning Algorithms to Evaluate L-dopa Response and Cognitive Impairment in ParkinsonCb,b"s Disease by Motion Sensors and EEG Data"
291
Optimizing Deep Brain Stimulation Parameters in a GBA-related Parkinso's Disease Patient: a comparison of monopolar review, 3D-reconstructions and Beta-sensing"
292
Functional brain architecture is shaped by sex in drug naCB/ve Parknson's disease patients"
293
Handwriting in Parkinson s Disease: a study with artificial intelligence
294
Assessing ChatGPT ability to answer laypeople questions about Essential Tremor
295
Dynamic quantitative evaluation of axial postural abnormalities associated with Parkinson's disease: a pilot study.
296
The cerebellar cognitive affective syndrome in ET subtypes
297
Smell performances in patients with Bipolar Disorder and parkinsonian signs compared to Parkinson Disease and Healthy Subjects
298
THE WHISTLE-SMILE REFLEX IN PARKINSON'S DISEASE: A CROSS-SECTIONAL STUDY
299
Safinamide effect on sleep architecture of motor fluctuating ParkinsonCb,b"s disease patients: a polysomnographic rasagiline-controlled study"
300
The genetic landscape of Parkinson's Disease in an Italian cohort and the need for a standardized approach
301
Static postural control is affected even in mild Freezing of Gait in ParkinsonCb,b"s Disease"
DISORDINI DEL MOVIMENTO 3
25
596
Arm Swing Kinematics in Parkinson's Disease: Clinical Insights"
597
Body image appearance in Parkinson's disease patients on advanced therapies
598
Dysautonomia and cognitive impairment as clinical predictors of disease progression in patients with Parkinson's disease"
599
Transcranial alternating current stimulation of the cerebellum in cervical dystonia
600
RETINAL THICKNESS IN ESSENTIAL TREMOR PLUS (ET PLUS): CORRELATION WITH CLINICAL VARIABLES
601
Kinematic signature of rigidity during passive upper limb mobilization in patients with Parkinson's disease"
602
Neurophysiological and clinical effect of botulinum toxin in essential blepharospasm
603
Opicapone improves end-of-dose neuropsychiatric fluctuations in patients with Parkinson disease: a 6-month follow-up study
604
Management of PEG-J related complications in advanced Parkinson's disease patients: a monocentric experience
605
The role of pathology validation on the association between smoking and Parkinson's Disease
606
GALC variants in adult patients with neurodegenerative diseases: results from LysoLate study.
607
Role of CITIcoline as supportive therapy in PARKinson's disease: the CITIPARK trial.
609
Genetic analysis in primary dystonia: a prevalence study in patients followed up to Gemelli Hospital in Rome
610
Patient Experience and Treatment Satisfaction with Continuous Subcutaneous Infusion of Foslevodopa/Foscarbidopa for Treatment of Advanced Parkinson's Disease "
611
Acknowledging the responses of diverse motor phenotypes to Levodopa-Carbidopa Intestinal Gel in advanced Parkinson's Disease. A prospective observational study.
612
Acute challenge with levodopa Parkinson's disease with dementia and Dementia with Lewy bodies. "
613
A pathology-validated study to investigate the role of Uric Acid in Parkinson's Disease
614
Characterizing Neurophysiological Alterations in Stroke Patients Using high-density EEG and Fuzzy Entropy Analysis During Gait and Resting-State
615
Gender-Specific Cardiovascular Autonomic Responses in Parkinson's Disease: Insights from an Observational Study.
616
Parkinson's disease and chronic inflammatory demyelinating polyneuropathy: broadening the clinical spectrum of VCP mutations?"
617
Dopa responsive dystonia due to GCH1 gene variant mimicking hereditary spastic paraparesis.
618
Bilateral thalamic DBS in Holmes Tremor: a dynamic management of a disabling symptom.
619
KPNA3-related hereditary spastic paraplegia and a de novo variant in GCH1: partners'crimeC"b,B or independent findings?"
620
MAGNESIUM INFLUENCE ON THE CENTRAL NERVOUS SYSTEM: A CASE OF HYPOMAGNESEMIA-INDUCED ACUTE CEREBELLAR SYNDROME
621
ATYPICAL ONSET OF HUNTINGTON DISEASE: A CASE OF PRESENTATION WITH FREEZING OF GAIT
DISORDINI DEL MOVIMENTO 4
22
874
A novel TCF20 pathogenic variant associated with myoclonus and intellectual disability: a case report.
875
Writhing movements as clinical presentation of Multiple Sclerosis
876
Defining the intermediate allele phenotype in the huntingtin gene
877
A case of right parietal lesion associated with homolateral imitative synkinesis
878
PHENOTYPIC VARIABILITY IN JUVENILE-ONSET HUNTINGTONC'S DISEASE: A CASE REPORT OF A PERUVIAN PATIENT"
879
Acute onset of bilateral choreiform movements in a 72-year-old woman with lung transplant and iatrogenic diabetes mellitus.
880
NEUROLOGICAL COMPLICATIONS INDUCED BY NIVOLUMAB: A CASE REPORT
881
Catatonia in a patient with daily intermittent hypoglycemia
882
Progranulin and neurodegenerative diseases: two clinical cases of patients diagnosed with Parkinson's disease and heterozygous mutation for the progranulin gene"
883
An atypical case of Progressive Supranuclear Palsy with predominant bulbar involvement and central hypoventilation.
884
Pseudo-orthostatic tremor in Graves' disease: a possible early sign of parkinsonism?"
885
Parry-Romberg syndrome in an elderly patient: a case report
886
Severe Cerebellar Dysfunction and Cognitive Impairment in a 60-Year-Old Female with DNMT3A Gene Mutation
887
Posterior Cord Myelopathy in a patient with copper deficiency.
888
GAD Antibody-Spectrum Disorders and Cerebellar Involvement: A Case Report
889
An isolated pharyngeal tremor mimicking a palatal tremor
890
A case of secondary brain calcifications
891
A case Parkinson's disease in a CADASIL patient
892
CASE REPORT OF ATYPICAL PARKINSONISM WITH A PSP/MSA OVERLAPPING MANIFESTATION: A DIAGNOSTIC CHALLENGE .
894
Enterovirus encephalitis, a rare cause of chorea.
895
Acute hemiballismus-hemichorea due to nonketotic hyperglycaemia: a case report
896
Different medical approaches to treat a post-surgical Hemiballismus-hemichorea syndrome
EPILESSIA 1
14
321
The Intersectoral Global Action Plan in Sub-Saharan Africa: an italian intervention model for epilepsy care
322
Sleep disorders and Minor Motor Events in sleep in temporal lobe epilepsy.
324
Neuroimaging as a SUDEP predictor: what is known and what still needs to be uncovered? A systematic review with single-data patient analysis.
325
Evaluating Diagnostic and Therapeutic Strategies for Late-Onset Epilepsy Among Italian Epileptologists: Toward a Standardized Approach
326
RELIABILITY OF HOME-VIDEO RECORDING IN DIFFERENTIATING SLEEP-RELATED HYPERMOTOR EPILEPSY FROM DISORDERS OF AROUSAL
327
Heart Rate Variability (HRV) demonstrates a decreased vagal output in patients with status epilepticus developing Tako-Tsubo cardiomyopathy
331
Perampanel in post-stroke epilepsy as only add-on: data from an Italian multicenter, retrospective, observational study.
332
Association between Revascularization Therapies and Post-Stroke Epilepsy: A Prospective Observational Case-Control Study.
334
Ketamine for the treatment of super-refractory status epilepticus (SRSE): the experience of the University Hospital of Trieste
335
Serum concentration and concomitant use of strong enzyme-inducing antiseizure medications: a real-world study in epileptic patients treated with brivaracetam
336
Cenobamate modulates EEG microstates enhancing epilepsy network in patients with drug-resistant temporal lobe epilepsy
337
Retrospective single center analysis on GAD65 related-epilepsy cohort: expanding the spectrum of autoimmune polyglandular syndrome
338
Cenobamate in Focal Epilepsy: a retrospective multicenter real-world study from Epi-To Network
339
Consumption, prescription appropriateness and demographic profile of Cenobamate users in a University Hospital (2022-2023)
EPILESSIA 2
17
642
Is all that glitters gold? Monocentric experience on the real-world use of Cenobamate
644
Therapeutic Management and Clinical Outcomes of Autoimmune Encephalitis-associated Status Epilepticus: a Case Series
645
KCNT1-Related Epilepsy: description of two cases
646
Mindflulness based terapy for treatment of Psychogenic Non Epileptic Seizures (PNES): a pilot study
647
Abdominal pain as an atypical manifestation of frontal lobe epilepsy
648
Unmasking the Mimic: focal status epilepticus associated with subdural empyema mistaken for hematoma
649
VNS and Cenobamate: A potential new run against Ultra-refractory focal lesional epilepsy?
650
POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME
651
From Seizures to Cognitive Decline: Diagnostic Challenges in Anti-CASPR2 Antibody-Associated Limbic Encephalitis
652
Fire and blood: investigating the role of inflammation and genetics in a case of drug-resistant epileptic encephalitis
653
Focal negative motor seizures: a video-EEG and polygraphy co-registration study
654
Impact of the COVID-19 pandemic, its related social restriction measures and vaccination campaign on emergency department attendances for epileptic seizures: An interrupted time-series analysis
655
Foramen ovale electrodes in Anti-GAD musicogenic seizures reveal bilateral indipendent temporo-mesial involvement
656
Successful management of medically refractory seizures with MRgFUS: our experience and literature review of a novel promising disconnection surgery
657
What glitters is not always gold: an acute case of porphyria and differential diagnosis with autoimmune encephalitis
658
Focal seizures and unihemispheric atrophy in an HIV patient: a Rasmussen-like syndrome
659
Role of Perampanel in the Treatment of SMART Syndrome (Stroke-like Migraine Attacks after Radiation Therapy): A Case Report
EPILESSIA 3
16
898
Lennox-Gastaut Syndrome in a Patient with a De Novo Mutation in TUBB2A
899
A case report showing a rare MT-ND5 gene mutation associated with seizures, myoclonus and multiple brain MRI stroke-like lesions.
900
Oculoleptomeningeal amyloidosis presenting with prolonged post-ictal state and relapsing visual loss
901
Shiga toxin-producing Escherichia coli infection-related acute encephalopathy
902
New onset refractory status epilepticus (NORSE) associated with anti Hu-antibody encephalitis and hyponatremia
903
PARP6 Identified as a Novel Causative Gene in a Syndrome Characterized by Neurodevelopmental Disorders and Epilepsy
904
Cefepime-induced neurotoxicity, a case report
905
Vanishing Lesions of the Central Nervous System and the role of Corticosteroid Therapy, a Case Series
906
Bariatric surgery and drug-resistant epilepsy Cb,b Case series"
907
Adult-onset Electrical Status Epilepticus during slow-wave Sleep (ESES) in a patient with intellectual disability
908
Cenobamate as treatment for pediatric Drug-Resistant Epilepsy associated with 15q13.2q13.3 microdeletion: a case report
909
Recurrent nonconvulsive status epilepticus in a patient with epileptic encephalopathy due to SCN8A mutation
910
Movement-Induced Seizures Post-Stroke: A Case Report
912
PNES, the important role of the patient history
913
Reversible Subcortical Dark White Matter in Status Epilepticus
914
A case of spastic paraparesis and generalized non-motor seizures in a patient with seropositive Anti-GluR3 antibodies
MALATTIE CEREBROVASCOLARI 1
21
201
Defining the short-term outcome of minor ischemic stroke due to small artery occlusion in the era of dual antiplatelet treatment
204
Prediction of acute ischemic stroke severity combining Artificial Intelligence and EEG connectivity analysis
205
Recurrent ischemic stroke and its etiology in patients with minor ischemic stroke or high-risk TIA Cb,b a subgroup analysis from the READAPT study. "
206
GAIN and LOSS of CARDIAC FUNCTION in CEREBROVASCULAR DISEASE
207
CAN BETA-BLOCKERS BE USEFUL TO ANTAGONIZE STROKE HEART SYNDROME?
208
IMPLANTING CARDIAC MONITORS IN ESUS PATIENTS: USEFUL OR FUTILE?
209
ISCHEMIC STROKE: JUST A MATTER OF ARTERIES? HAMPERED VENOUS EGRESS AFTER SUCCESSFUL THROMBECTOMY CORRELATES WITH POOR CLINICAL OUTCOME.
210
Role of cerebral hemodynamics in White Matter Hyperintensities and impact on cognitive and clinical outcomes in a cohort of patients with TIA/non-disabling stroke
211
Posterior cerebral circulation in children with Sickle Cell Disease: an uncharted territory
212
Unsupervised machine learning in a real-world dataset: cluster analysis of clinical evolution patterns among patients with acute ischemic stroke. The SIBILLA project.
213
Prolonged heart rhythm monitoring with Rooti-RX supracutaneous device and loop recorder after PFO closure
214
The intracerebral hemorrhage bundle of care in the real world: results from a prospective stroke registry
215
Imaging Patterns and Prognosis of Small Subcortical Infarcts
216
Statin use and long-term risk of recurrent intracerebral haemorrhage: The MUCH-Italy
217
CT Perfusion in posterior circulation stroke (PCS): clinical signs as useful predictors of perfusional abnormalities?
221
Exploring the impact of reperfusion therapy vs conservative management in acute stroke patients with premorbid disability
222
Patient-Reported Outcome Measures (PROMs) to Predict Stroke Recurrence: Insights from a Multicenter Study
223
Thyroid hormone levels as predictors of acute ischemic stroke severity on admission: could there be a role?
224
Gender-differences in young adult patientsCb,b" ischemic stroke outcome after revascularization treatment: a single center case series"
225
Real-world experience with andexanet alfa for reversal of Factor Xa inhibitors in patients with intracranial bleeding
226
Recurrent Transient Global Amnesia: a rare familial variant
MALATTIE CEREBROVASCOLARI 2
18
227
Cerebral Amyloid Angiopathy in AlzheimerCb,b"s Disease: A Comparison between Different Versions of the Boston Criteria"
229
Polysomnographic parameters as predictors of outcome in patients with ischemic stroke
230
Prognostic Significance of triglyceride-glucose index in acute intracerebral hemorrhage
231
Clinical and Radiological Features in Acute Ischemic Stroke Patients with Atrial Fibrillation treated with Direct Oral Anticoagulants: A Retrospective Study.
232
ISCHEMIC STROKE ON DOAC: RARE BUT OFTEN DISASTROUS
233
Thrombus analysis in cancer-related stroke patients
234
Longitudinal hemodynamic correlates of vascular cognitive impairment: a transcranial doppler sonography follow-up study
235
Efficacy and safety of thalidomide in cerebral cavernous malformations associated hemorrhages.
236
ASSOCIATIONS BETWEEN HEART AND BRAIN PARAMETERS IN OLDER PATIENTS ON ORAL ANTICOAGULANTS FOR ATRIAL FIBRILLATION: STRAT-AF 2 STUDY
239
Modification of cerebrovascular vasoreactivity parameters as an expression of Cb,Eischemic pre-conditioningC"b,B ?"
240
CAROTID EAGLE SYNDROME (CES): A POSSIBLE CAUSE FOR UNDETERMINED ISCHEMIC STROKE
241
ISCHEMIC STROKE ON DOAC: ADHERE TO THE GUIDELINES
245
Systematic research for Right-to-Left Shunt, Deep Vein Thrombosis, and Occult Neoplasia in Patients Over 60 years old with Cryptogenic Ischemic Stroke
246
Missense c.3712C>T (p.Arg1238Cys) mutation in COL4A1 gene and spontaneous Cervical Artery Dissection (sCeAD): the case of two Italian siblings.
247
The strange cases of Functional Neurological Disorders miming a stroke: acute identification in the emergency addressing the risk
249
Exploring Vertebral Artery Stump Syndrome Syndrome: an overlooked cause of posterior ischemic strokes
250
Dysthyroidism and Ischemic Stroke: analysis of a population from Sicily and endemic areas for iodine deficiency.
251
GENDER-RELATED DIFFERENCES IN PATIENTS WITH ACUTE ISCHEMIC STROKE TREATED WITH REPERFUSION THERAPIES.
MALATTIE CEREBROVASCOLARI 3
24
571
ALTEPLASE FOR ACUTE CENTRAL RETINAL ARTERY OCCLUSION: CASE REPORT OF FOUR PATIENTS TREATED AT A UNIVERSITY HOSPITAL
572
Acute stenting for symptomatic pediatric focal cerebral arteriopathy: a case report
573
Simultaneous ischaemic stroke and acute intracranial haemorrhage: where does the balance underlie? A case report and a narrative review.
574
Unraveling Alexia: A Diagnostic Challenge and Therapeutic Opportunity in Stroke Rehabilitation
575
Reversible coma related to transient midbrain compression as unique manifestation of cerebral amyloid angiopathy-related inflammation: a case report.
576
Acute Psychosis After Right Thalamic Stroke Mediated By Frontal Dysconnection: A Case Report
577
Hypocalcemia presenting as a stroke mimic
578
A case of vascular parkinsonism in the context of mixed intracerebral hemorrhage
579
Early introduction of anticoagulant therapy after Heidelberg PH1 hemorrhagic infarction of ischemic stroke treated with intravenous thrombolysis: a case report
580
Management of the anticoagulant therapy after atypical hemorrhages in patients with no AF: two cases and a literature review
581
Embolic Stroke of Undetermined Source and Embolic Shower - A Challanging Case Report
582
Severe hypomagnesemia mimicking acute stroke: a case report
583
Cerebral amyloid angiopathy-related inflammation: a case report
584
Management of anticoagulant treatment in a case of relapsing ischemic stroke patient with atrial fibrillation and sleeve gastrectomy
585
Cerebral flow dysregulation encephalopathy following carotid stenting procedure: multiparametric CT and EEG characteristics
586
Can pontine paramedian infarct be caused by embolism? Three cases and a scoping review of the literature
587
A novel case of CARASAL, an extremely rare cause of stroke
588
Three cases of big basilar artery aneurysm: which conservative medical treatment is the best one?
589
Posterior reversible encephalopathy syndrome induced by bicalutamide: a case report and literature review
590
HSV1 and Acute Arterial Stroke in Children: case report and review of literature
591
PARAPARESIS DUE TO DORSAL SPINAL CORD ISCHEMIA DURING OZONE THERAPY FOR LOW BACK PAIN. A CASE REPORT
592
Which was the more convincing cause of stroke?
594
SUBACUTE AND PROGRESSIVE PEDIATRIC MOYAMOYA: a case report
595
Papillary muscular hypertrophy: unusual cause of cardioembolic ischemic stroke.
MALATTIE CEREBROVASCOLARI 4
20
851
The Eagle's jugular syndrome as cause of recurrent spontaneous intracranial hemorrhages and delayed intracranial hemorrages after neurosurgical interventions: A case report
852
Unveiling Bilateral Carotid Artery Dissection: the Importance of Collateral Circles.
853
A case of ischemic stroke and prostate cancer-associated non-bacterial thrombotic endocarditis
856
Contrast induced cerebral vasospasm following endovascular treatment of ICA intracranial aneurysm: a case report
857
CAA-ri mimicking and misdiagnosed as PRES: a case report
858
A CASE OF RADIOLOGICAL MISDIAGNOSIS: STROKE OR TUMOR?
859
ISCHAEMIC STROKE IN PREGNANCY: DISCUSSION OF A CLINICAL CASE
860
A case of alien hand syndrome in a woman with contralateral paramedian ponto mesencephalic hemorrhage
861
Accessory middle cerebral artery and clinical impact on acute ischemic stroke management: a case report
862
Case report: A rare complication of subarachnoid hemorrhage.
863
A rare case of delayed-onset Autoimmune Heparin-induced Thrombocytopenia and Cerebral Venous Sinus Thrombosis: A Case Report.
864
Moyamoya disease with brainstem unilateral hypotrophy: a case report.
866
From broken brain to broken heart: a case series of six Takotsubo syndromes, following an acute ischaemic stroke
867
All's well that ends well: a favorable case of guidewire accidental rupture during thrombectomy for stroke
868
Brachio-crural acute neurogenic pain of a haemisoma: can a NIHSS 0 stroke be disabling?
869
Right frontal precentral stroke presenting with selective anarthria.
870
Stroke in Abiotrophia defectiva endocarditis. A case report
871
Pseudo-ulnar sensory loss: a stroke chamaleon
872
BEYOND THE SKIN: PSORIASIS AND STROKE, A CASE REPORT
873
Anticoagulation therapy in haemorrhage? A case of Isolated Cortical Vein Thrombosis
MALATTIE DEGENERATIVE
14
943
Adult onset atypical Pantothenate Kinase-Associated Neurodegeneration (PKAN) with long disease duration: a Sardinian-family case and Literature Review
944
Searching for Predictive Variables in the Development of Psychotic Symptoms in Alzheimer's Disease: A Machine Learning Approach
945
Sex Differences in Idiopathic REM Sleep Behavior Disorder: Insights from the FARPRESTO Cohort
946
EFFECTS OF REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION IN PARKINSON DISEASE
947
Neuropsychiatric Symptoms as Predictors of Cognitive Decline in Mild Cognitive Impairment: A Two-Year Longitudinal Study on MBI and Alzheimer's Disease Progression
948
Phenotypic differences related to age at onset in behavioral variant of fronto-temporal dementia
949
Relationship between survival rate and baseline assessment in prodromal behavioral frontotemporal dementia
950
Home-based transcranial alternating current stimulation over the precuneus in Alzheimer's disease: a double-blind, randomized, placebo-controlled trial followed by an open label phase"
951
X-LINKED ADRENOLEUKODYSTROPHY: CEREBRAL INVOLVEMENT IN A YOUNG WOMAN, A CASE REPORT
952
A new pathogenic variant of AARS2 gene causing leukoencephalopathy, progressive, with ovarian failure (LKENP).
953
Subacute degeneration of visual and pyramidal pathways: clinical and MRI evidence
954
A LOOK BEYOND PARALYSIS: AN UNUSUAL PRESENTATION OF PSP
955
Rest tremor in Corticobasal Syndrome: a Case Report
956
Presenilin-1 Mutation in Early-Onset Alzheimer's Disease with Spastic Paraparesis: experience from University of Pisa
MALATTIE DEL MOTONEURONE 1
17
302
PrimeC, An Oral Candidate for Amyotrophic Lateral Sclerosis, Meets Primary Safety and Secondary End Points in the Phase 2b PARADIGM Trial
303
Longitudinal progression of subcortical structural damage in amyotrophic lateral sclerosis
304
Cervical alterations in Hirayama disease: an MRI, FDG-PET and neurophysiological combined approach
305
Amyotrophic Lateral Sclerosis prevalence projection in 2040: a less rare disease.
306
Integrating Mind and Care: Evaluating the Influence of Cognitive and Psychological Factors on Advanced Directive Formulation in ALS Patients
307
Cognitive, behavioral and metabolic profile in the Amyotrophic Lateral Sclerosis Cb,b Frontotemporal dementia spectrum disorders. "
308
Challenges in diagnosing Cervical Lower Motor Neuron Syndromes: a comprehensive overview
309
3D printing: new tool for ALS upper limb orthosis.
310
Adherence and preferences on treatment with riluzole in patients with amyotrophic lateral sclerosis: a single-center survey
311
Temporal muscle thickness as marker of nutritional status in Amyotrophic lateral sclerosis: Insights from Bioimpedance Analysis.
314
Chest Dynamic MRI as Early Biomarker of Respiratory Impairment in Amyotrophic Lateral Sclerosis Patients: a pilot study
315
The other side of the coin in Amyotrophic Lateral Sclerosis: manual dexterity assessment with Coin Rotation Test
316
Prognostic value of systemic and neuroinflammatory biomarkers in Amyotrophic Lateral Sclerosis: a monocentric experience
317
Autozygosis analysis in Sporadic Amiotrophic Lateral Sclerosis: a population-based study
318
T regulatory cells and their subpopulations in Amyotrophic Lateral Sclerosis: insights from a longitudinal study
319
Peak Inspiratory Flow (PIF) as a marker of respiratory failure and survival in Amytrophic Lateral Sclerosis (ALS)
320
Metabolic and fluid biomarkers support a microglia-mediated inflammatory signature in ALS.
MALATTIE DEL MOTONEURONE 2
17
622
Assessment of motor endurance in spinal muscular atrophy through EnduSMA protocol: one-year follow-up data from a multicenter cohort study
623
Stem Cell-Derived Spinal Cord Organoid Model to Study the Molecular Consequences of Treatment with a Risdiplam-Analogue in Specific Time Windows and Cell-Specific Manner
624
IRON METABOLISM-GENETIC INTERPLAY IN AN ALS COHORT: A PRELIMINARY STUDY
625
Cerebrospinal fluid neurofilament light chain and KingCb,b"s college progression rate: insights from a pivotal study."
627
Unravelling the Complexity: A Case of Late-Onset ALS with Monomelic Involvement and SETX mutation
628
Hypoparathyroidism, a rare condition that can mimic ALS: a case report
629
ALS AND PARKIN
630
Management of pregnancy in the era of disease-modifying therapies for Spinal Muscular Atrophy: a case report
631
Duropathy as a rare motor neuron disease mimic: from bibrachial amyotrophy to infratentorial superficial siderosis
632
Behavioural impairment in Amyotrophic Lateral Sclerosis: a population-based study.
633
Progressive generalized muscular weakness debuted as a severe post-traumatic foot drop in a young man
634
Bibrachial amyotrophy as a rare manifestation of intraspinal dural leakage of cerebrospinal fluid, mimicking ALS
635
Bilateral Facial Palsy as a Presenting Symptom of Familial ALS: A Case Report
636
Brait-Fahn-Schwartz disease: where ParkinsonCb,b"s disease and amyotrophic lateral sclerosis meet. An Italian case report."
637
Visual Disturbances in an ALS Patient with SOD1 Mutation Undergoing Tofersen Therapy: A Clinical Case Study
639
Atypical parkinsonism presenting as an upper motor neuron syndrome: report of two patients
640
A new mutation in SOD1 amyotrophic lateral sclerosis: a case series
MALATTIE NEUROMUSCOLARI E MIOPATIE 1
25
110
DEMOGRAPHICS AND BASELINE DISEASE CHARACTERISTICS IN THE INEBILIZUMAB, A SELECTIVE CD19+ B CELL DEPLETER, GENERALIZED MYASTHENIA GRAVIS REGISTRATIONAL STUDY (MINT)
111
Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Efgartigimod PH20 in Participants With Generalized Myasthenia Gravis: Interim Results of the ADAPT-SC+ Study
112
Improvements in Pain and Quality of Life After Inebilizumab in Attack-Free NMOSD Participants
113
Achievement of Minimal Symptom Expression and Effect on Disease-Specific Measures in Acetylcholine Receptor Antibody-Positive Participants With Generalized Myasthenia Gravis Treated With Efgartigimod in ADAPT/ADAPT+
114
Safety of Inebilizumab in Participants over 50 and 65 years of age with Neuromyelitis Optica Spectrum Disorder (NMOSD)
115
Nipocalimab in Generalized Myasthenia Gravis: Results from a Double-Blind, Placebo-Controlled, Randomized Phase 3 Study
116
THYMECTOMY IN JUVENILE MYASTHENIA GRAVIS IS SAFE AND EFFECTIVE WHEN PERFORMED AT AN AGE GREATER THAN 12 YEARS: RESULTS OF A 15-YEARS FOLLOW UP STUDY
117
A seven-year real-world experience with nusinersen treatment in adult SMA patients at C. Besta Neurological Institute
118
Zilucoplan in generalized myasthenia gravis: early real-life experience
119
Efgartigimod in AChR-seropositive generalized myasthenia gravis: the impact on MG burden and usefulness in the real-life setting
120
Complement inhibitors drugs in generalized refractory Myasthenia Gravis
121
Safety and effectiveness of Mycophenolate Mofetil in generalized Myasthenia Gravis: a retrospective cohort multicenter study.
122
Myasthenia Gravis as part of the Graft-versus-host disease spectrum: a case description and review of literature.
123
Long term effectiveness of thymectomy in Late Onset Myasthenia Gravis (LOMG): a case-control study
124
Rapid onset of efficacy of Eculizumab in a single-center cohort of patients with refractory generalized Myasthenia Gravis
125
Role of eculizumab in treating impending exacerbations and myasthenic crysis
126
FAST RESPONSE TO ECULIZUMAB AS RESCUE THERAPY IN A PATIENT WITH MYASTHENIC CRISIS AT DISEASE ONSET.
127
Ravulizumab use in Myasthenia Gravis: a case report
128
Myasthenia gravis treatment in active oncologic patients: a case report.
129
Corticosteroid dose tapering during treatment with zilucoplan in patients with generalised myasthenia gravis: 120-week follow-up of RAISE-XT
130
Nipocalimab Dose Selection for A Phase 3 Study in Adult Patients with Generalized Myasthenia Gravis
131
Drivers of new rozanolixizumab treatment cycles in patients with generalised myasthenia gravis in the Phase 3 MycarinG and open-label extension studies
132
Long-term safety and efficacy of zilucoplan in myasthenia gravis: Additional interim analyses of RAISE-XT
133
Bolus and secretion management in Myotonic Dystrophy Type 1: does it all depend on swallowing impairment?
134
GAIT PARAMETERS / COGNITIVE FUNCTION CORRELATION IN A COHORT OF PATIENTS WITH MYOTONIC DYSTROPHY TYPE 1: A SINGLE-CENTER SENSOR-BASED GAIT ANALYSIS
MALATTIE NEUROMUSCOLARI E MIOPATIE 2
23
471
A Cohort Study on Cognitive Functioning in Myasthenia Gravis
472
Complement Factor C5 Inhibitors in AChR-seropositive Generalized Myasthenia Gravis: a comparison in the real-life setting.
473
Motor Unit Number estimation (MUNE) test as assessment tool for motor impairment in Charcot Marie Tooth Disease
474
Steroid-sparing effect of complement inhibitors therapy in patients with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis
475
Comparison of fixed cell-based assay to radioimmunoprecipitation test for anti-AChR and anti-MuSK antibodies in Myasthenia Gravis patients
477
Introducing the SPS-ADL Score: A Simple Tool for Assessing the Impact of Stiff Person Syndrome on Daily Living in anti-GAD Spectrum Disorders
478
Use of Eculizumab as a Rescue Strategy in Refractory Generalized Myasthenia Gravis: a Case Report.
479
Kaposi's sarcoma in myasthenia gravis patient under oral steroids treatment: two case reports."
481
Role of muscle biopsy in mitochondrial myopathy: genotype-phenotype correlation.
482
Serum neurofilament light chain seems not a useful biomarker of central nervous system involvement in Late onset Pompe disease (LOPD)
483
Clinical variability and molecular complexity of FSHD: relevance of deep phenotyping and comprehensive genetics in characterizing atypical clinical cases
484
Muscle ultrasound in Inclusion Body Myositis
485
Subjective assessment of sleep quality in adult patients with dystrophinopathy: a single centre experience
486
A complex presentation of mitochondrial myopathy
487
COLQ-Related Congenital Myasthenic Syndrome: Two Illustrative Cases and Therapeutic Implications
488
A rare late-onset LRP4/CHRND-related congenital myasthenic syndrome: a case report.
489
A case of aggressive relapsing isolated orbital myositis leading to monocular blindness
490
SEPN1-RELATED MYOPATHY WITH ACUTE RESPIRATORY ONSET IN MIDDLE AGE: A CLINICAL AND GENETIC STUDY
491
Tired of Myotonia? An incidental diagnosis of myasthenia gravis in a patient with Thomsen's disease.
492
Ptosis and Diplopia in Thymoma: Myastenia Gravis or Paraneoplastic Rhomboencefalopathy? A challenging diagnosis.
493
Clinical and molecular complexity in desminopathy: description of a novel variant in DES gene
494
Unique case of a patient diagnosed with Facioscapulohumeral Dystrophy, Myasthenia Gravis, and Psoriatic Arthritis: Fortuitous association or correlation?
495
MYASTHENIA GRAVIS AND POLYMYOSITIS OVERLAP AS PARANEOPLASTIC SYNDROME: A CASE REPORT
NEUROCOVID
5
782
Breakthrough COVID-19 in people with multiple sclerosis on disease modifying treatments: is it still a severe disease?
783
Neuropsychiatric sequelae of SARS-CoV-2 infection in solid organ transplant recipients
784
Association of cerebral amyloid angiopathy-related inflammation and raised anti-amyloid autoantibodies after COVID-19 vaccination.
785
NeuroCOVID as risk factor for cognitive decline
786
Acute haemorrhagic cerebellitis as unusual presentation of COVID19-related encephalitis: a case report.
NEUROFISIOLOGIA CLINICA E NEUROSCIENZE DI BASE
19
135
Toward novel quantitative-EEG biomarkers of cognitive performance in People with Epilepsy
136
Clinical efficacy of Low-Dose Perampanel Correlates with Neurophysiological Changes in Familial Adult Myoclonus Epilepsy
137
Neurophysiological biomarkers in adults with type III Spinal Muscular Atrophy
138
Electromyography findings and their value in Stiff Person Spectrum Disorder: more than meets the eye
139
ELECTROPHYSIOLOGICAL DETECTION OF SITE OF LESION IN LONG-TERM COVID-19 SMELL DEFICITS
140
P100 latency on visual evoked potentials as a marker for demyelinating diseases of the central nervous system "meta-analysis"
141
Reverse Split Hand as a Neurophysiological Hallmark of Spinal Muscular Atrophy
142
Neurophysiological correlates of limb-kinetic apraxia in Parkinson's disease
143
Tremor during walking in Parkinson's disease: a neurophysiological assessment
144
Progressive encephalopathy in m.3243A > G/MT-TL1 mutation carriers: a quantitative EEG analysis
145
Mapping motor cortical network excitability and connectivity changes in de novo Parkinson's disease"
146
Assessing the Role of Theta Rhythm Activity in Cervical Dystonia
148
Electrokinesigraphic study in patients with Parkinson's disease: effects of dopaminergic therapy on swallowing physiology
149
EEG brain functional connectivity in ParkinsonCb,b"s disease: a comparative analysis of sporadic and genetic forms in ON/OFF therapy"
151
Attentional functioning in Parkinson's Disease with Freezing of Gait: preliminary data from ERPs
152
Compound muscle action potential amplitude ratio to distinguish CMT1A from CIDP: a single-center experience
153
Safinamide might mitigate dopamine-induced oxidative stress in neuronal cells
154
Head circumduction induced post-rotatory torsional nystagmus: a proof-of-concept study
155
AN IMMUNOHISTOCHEMICAL STUDY ON SEROTONERGIC NEURONAL CELL BODIES AND PROCESSES IN THE HUMAN CEREBELLUM
NEUROGENETICA MALATTIE RARE E NEUROLOGIA DELL'ETA' EVOLUTIVA 1
17
555
CANVAS: not the usual pentanucleotide.
556
THE IDENTIFICATION OF A NOVEL VARIANT OF NICOTINIC ACETYLCHOLINE RECEPTOR GENE CHRNA2 IN ITALIAN PATIENT WITH FEBRILE SEIZURES
557
Genetic Mutations in Early Onset Dementia: a five-case series
558
Clinical spectrum of Nasu-Hakola Disease (NHD): a report of two cases from an Italian referral center and review of the literature.
559
Ataxic Syndromes and CoQ10 Metabolism Defects: Clinical Characteristics of a Case Series
560
High burden of cardiovascular risk factors and low ischemic stroke prevalence in Myotonic Distrophy type 1: what are we missing?
561
SPG 79 A, the First Italian Case Described: A Novel UCHL1 Mutation expands our understanding
562
A new c.1988G>A MFN2 mutation associated with familial optic neuropathy without polyneuropathy
563
Transient neurological deficits and small fiber neuropathy in a patient with multiple variants in collagen genes
564
Beyond monogenic inheritance: pure hereditary spastic paraplegia phenotype in a patient carrying heterozygous mutations in the SYNE1 and CAPN1 genes.
565
Genetic analysis of GBA gene in a cohort of patients with ParkinsonCb,b"s Disease"
566
Brain and spinal lesions responsive to steoroid in a patient with hetherozygous mutation for succinate dehydrogenase subunit B: a case report.
567
Clinical and genetic features in Hereditary Spastic Paraplegia type 5: multisite assessment of the RIN-Italian Virtual Institute of Rare Disease
568
Identifying Gerstmann-StrCB$ussler-Scheinker syndrome phenotypes associated with PRNP P102L variant using Machine Learning clustering
569
Primary results from HELIOS-B, a phase 3 study of vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy
570
Shall we treat children with migraine?
839
LMNB1-Related Autosomal Dominant Leukodystrophy: Diagnostic Insights from Newly Identified Cases in Two Families
NEUROGENETICA MALATTIE RARE E NEUROLOGIA DELL'ETA' EVOLUTIVA 2
10
837
A novel de novo GFAP mutation leads to juvenile-onset Alexander Disease presenting with bilateral vocal cord paralysis
838
Serum biomarkers in Primary Mitochondrial Diseases with different organ involvement. Data from a single center experience
840
Clinical and genetic description of a case series of ALS patients carriers of KIF5A mutation
842
Atypical clinical manifestations challenging the differential diagnosis of Benign Hereditary Chorea
843
Neurophtalmological phenotype of two siblings affected by SPG26 spastic paraplegia
844
A rare cause of abducent nerve palsy: Langerhans cell histiocytosis. Case report and literature review
845
Extending the clinical and radiological spectrum of SCA50 (NPTX1)
847
A case of IgG4-related pachymeningitis
848
Childhood primary stabbing headache: a double center study
849
Pediatric arterial ischemic stroke: a single center's experience
NEUROIMMAGINI 1
17
184
In-Vivo Assessment of Cellular Soma and Neurite Density Abnormalities in Multiple Sclerosis Paramagnetic Rim and Core-Sign Lesions
185
Spinal cord gray matter atrophy predicts disability progression in multiple sclerosis
186
Glymphatic clearance in CADASIL patients: a DTI-ALPS study
187
Identification of ParkinsonCb,b"s disease biomarkers in a multi-modal AI framework using raw MRI and clinical data"
188
Glymphatic dysfunction in clinical phenotypes of motor neuron disease
189
Microstructural brain alterations in Trigeminal Neuralgia: insights from multi-shell diffusion brain MRI analysis
190
Neural correlates of central pain in Trigeminal Neuralgia: a functional MRI analysis
191
Left putaminal predominance of nigrostriatal deficit in Parkinson Disease associated with REM sleep behavior disorder
192
Alterations of brain structural covariance in Parkinson Disease: a pilot study
193
CHRONIC SLOWLY EXPANDING LESIONS ACCUMULATE MORE THAN ACUTE NEW LESIONS IN THE BRAIN OF RRMS PATIENTS TREATED WITH PLATFORM THERAPIES.
194
Mild microstructural diffuse tissue damage in MOGAD as assessed by magnetization transfer ratio imaging
195
Patterns of brain hypometabolism in the behavioral variant of AlzheimerCb,b"s disease"
196
Characterizing diffuse and focal Grey Matter damage with Soma and Neurite Density Imaging metrics in Multiple Sclerosis
197
The ability of cognitive demanding verbal fluency tasks in identifying early stages of dementia
198
Unveiling the structural neural network of Freezing of Gait in ParkinsonCb,b"s Disease: a coordinate-based network approach. "
199
White matter hyperintensities in acromegaly: what's the role of different comorbidities?
200
Impaired emotional processing and reduced System Segregation in Insular stroke
NEUROIMMAGINI 2
15
537
Characterization of corpus callosum pathology in mesial temporal lobe epilepsy using quantitative brain relaxation atlases
539
The role of central vein sign and paramagnetic lesions in differentiating MOGAD from MS patients
540
Mapping electrophysiological activity changes in perilesional regions and their relationship with acute stroke impairments
541
Decision making under ambiguity associates with mesial temporal lobe thickness in Subjective Cognitive Decline individuals
542
Disconnection of Cerebellar Motor Areas and Motor Impairment in Multiple Sclerosis
543
Dynamics of choroid plexus volume is associated with the presence and development of fatigue in multiple sclerosis
544
Structural connectivity differences in Essential Tremor with and without Rem Sleep Behaviour Disorder
545
Delayed radiation-induced cerebral necrosis following treatment of an intracranial rhabdomyosarcoma, a case study
546
AMYGDALA ENLARGEMENT AND TEMPORAL LOBE EPILEPSY
548
Cortical folding metrics and brain metabolism in early Alzheimer's disease
550
Triceps surae muscles echo intensity in people with spasticity: the effect of muscle involvement and botulinum toxin treatment
551
Cognitive reserve associates with emotional processing in the AD continuum: any evidence for an emotional reserve?
552
An atypical case of Tolosa-Hunt syndrome associated with herpetic infection
553
Hodgkin Lymphoma presenting with dorsal compressive myelopathy
554
Dark White Matter
NEUROIMMUNOLOGIA NEUROINFETTIVOLOGIA 1
19
516
Epidemiology and clinical characteristics of autoimmune encephalitis in the province of Verona, Italy
517
Intravenous immunoglobulin bridging for rituximab delayed efficacy in refractory autoimmune encephalitis: single-center experience
518
Opsoclonus-myoclonus syndrome and myelitis: a rare presentation of anti-Ri paraneoplastic neurological syndrome
519
Frequency of LRP4 antibodies using a newly implemented assay in a consecutive cohort of suspected Myasthenia Gravis patients
520
Bing-Neel syndrome unmasked: a Varicella Zoster Virus meningoradiculitis conceals a rare clinical entity
521
Isolated neuropathic pain in CASPR2 antibodies spectrum disease: case report and systematic review
522
CNS damage and inflammatory profile associated to CNS infections: a retrospective study
524
Isolated optic neuritis in sarcoidosis mimicking lymphoma: a case report
525
Anti-mGluR1 encephalitis: description of a case
526
Isolated Neurological Presentation of Lyme Disease in Non-Endemic Area
527
ANTI-NMDA RECEPTOR ENCEPHALITIS AND MULTINODULAR GOITER: A CASE REPORT
528
A perspective open label study on FcRn inhibitors in anti-GAD-seropositive Stiff Person Syndrome
529
Acute postinfectious leukoencephalitis with bilateral hemispheric edema: a life-threatening entity
531
An extended inflammatory, neuronal and glial CSF marker panel in encephalitis: the Bio-ENCOVID multi-center study
532
The Cb,EInsular Knife-CutC"b,B Sign in Patients with Suspected Encephalitis"
533
Do Immune Checkpoint Inhibitors Affect the Course of Multiple Sclerosis? A systematic review and meta-analysis
534
Immunoadsorption for myasthenia gravis and neuromyelitis optica: a single center experience
535
Seronegative autoimmune encephalitis in a patient with GoodCb,b"s syndrome"
536
Epstein-Barr virus encephalitis showing bilateral VI cranial nerve palsy in an immunocompetent 18-year-old girl
NEUROIMMUNOLOGIA NEUROINFETTIVOLOGIA 2
14
818
Seasonal Variation in Myasthenia Gravis Incidence
819
The role of brain FDG-PET as a marker of disease activity in anti-CASPR2 encephalitis: A case report
820
Delayed carryover progressive multifocal leukoencephalopathy in patients with non-Hodgkin follicular lymphoma treated with obinutuzumab: a possible class effect and need for surveillance
821
False positive AChR antibodies in a case of foodborne botulism
822
Saccharomonospora glauca isolated from CSF in a case of meningoencephalitis: a case report
823
A young woman with Neuromyotonia, Neuromyelitis Optica, Myasthenia gravis and Systemic Lupus Erythematosus: looking for tolerance
825
MOG-IgG and radiological leukodystrophy-like patterns in patients with genetic and inflammatory disorders: case report and a literature review
826
Friend or Foe? When Immunotherapy unlocks the door to Autoimmunity: a Case Report of MOGAD Triggered by Pembrolizumab in a Patient with Gray Zone Lymphoma
827
Anti-N-methyl-D-aspartate (anti-NMDA) receptor antibody encephalitis in a male adolescent with Klinefelter-associated teratoma-choriocarcinoma
828
Exploring different neurological phenotypes in systemic lupus erythematosus: a case series
831
BannwarthCb,b"s lymphocytic meningoradiculitis in a non-endemic area: implications on differential diagnosis and management."
832
Tocilizumab treatment in naCB/ve adult MOGAD patients: a single center experience
833
Linking the unseen: Marchiafava-Bignami Disease and Tuberculous Meningo-myelitis.
834
Challenges in Diagnosis and Management: A Case of Non-Infectious Rhombencephalitis
Neurologia Cognitivo Comportamentale / Neuropsicologia clinica 1
15
660
The emerging role of the cerebellum in the affective theory of mind in the Behavioral Variant of Frontotemporal Dementia
661
The sensitivity of novel experimental tasks assessing associative memory and pattern separation for the detection of Subjective Cognitive Decline: preliminary findings of a neuropsychological and brain volumetric study
662
Lesion topographies and their functional connections contribute to identify networks of cognitive impairment in multiple sclerosis patients: a 3T lesion network mapping MRI study
663
Exploring the relationship between consolidated resilience and inter-network connectivity in adult and pediatric multiple sclerosis
664
Empathic capabilities and emotion recognition impairment across the PPA spectrum
665
Role of Rey Auditory Verbal Learning TestCb,b"s and Short Story recallC"b,b"s sub-measures in predicting cerebrospinal fluid AlzheimerC"b,b"s disease profile in MCI patients"
666
A common marker of emotion recognition dysfunction in the FTLD spectrum of disorders
667
Resting state connectivity and the assessment of Personality in patients with temporal lobe epilepsy
668
Remote Cognitive Stimulation in ParkinsonCb,b"s Disease Patients with Mild Cognitive Impairment: the STIMO.TE-Rehab Project."
669
Gerstmann syndrome: is it so rare? A cross-sectional prevalence study in patients with neurocognitive disorders
670
Rubber Hand Illusion in ParkinsonCb,b"s disease"
671
How to detect emotion recognition alterations in amyotrophic lateral sclerosis
672
The neuropsychological profile of people with clinically isolated syndrome (CIS): a meta-analysis
673
Salience and executive control networks time-varying connectivity and cognitive impairment in neuromyelitis optica spectrum disorder
674
Cognitive and affective aspects of Theory of mind are differently affected in the continuum of Alzheimer disease.
Neurologia Cognitivo Comportamentale / Neuropsicologia clinica 2
13
915
Exploration of apathy and its cognitive, emotional-affective and auto-activation dimensions in Subjective Cognitive Decline
916
Lab and at-Home tDCS combined with Cognitive Rehabilitation improves Cognitive Outcomes 2-years after a TBI: A Case Study
917
Effectiveness of i-Virtual Reality and Telemedicine based cognitive rehabilitation on Prospective Memory in ParkinsonCb,b"s disease with Mild Cognitive Impairment: a placebo-controlled trial"
918
Cognitive and behavioural changes in relation to the presence and reversion of impulse control disorder in patients with Parkinson's disease
919
Cognitive reserve predicts long-term cognitive trajectories in relapsing-remitting multiple sclerosis: a 6.5-years follow-up study
920
SOCIAL COGNITIVE ABILITIES ACCROSS DISEASE PROGRESSION: THEORY OF MIND IN EARLY AND MID-STAGE HUNTINGTONCb,b"S DISEASE PATIENTS"
921
Determinants of stigma experience in patients with Multiple Sclerosis
922
Clinical Features, Neuropsychological Profile and Progression of Mild Cognitive Impairment in Psychiatric Disorders
923
Beyond the language: neuropsychological profile in a cohort of patient with Primary Progressive Aphasia
925
Theory of mind and limbic encephalitis
926
COGNITIVE IMPAIRMENT POST STROKE: A RANDOMIZED TRIAL ON THE EFFICACY OF TELEREHABILITATION. THE CIPS-TER STUDY: RATIONALE, DESIGN AND METHODOLOGY.
927
Preventing cognitive decline and dementia through an innovative immersive virtual reality and telemedicine-based multi-component intervention: study protocol of a randomized controlled trial
928
Validation of the italian version of the MacArthur Competence Assessment Tool for Treatment (MacCAT-T) in an italian population of individuals with cognitive impairment
NEUROONCOLOGIA
11
157
Deciphering glioblastoma metabolic signature: molecular profiling and NADH-FLIM imaging
158
A case report of Brain Amyloid accumulation after Carbon Ion Radiotherapy
159
Drug sensitivity of Recurrent GBM patient-derived organoids correlates with patientsCb,b" response to second line chemotherapy "
160
Neuropsychological impact of second-surgery in high-grade glioma patients
161
When a patient has two tumors and a leptomeningeal spread: a case report
162
Neuroimaging and Neuropsychological Features of Hypothalamic Syndrome
164
IgG4RD presenting as spinal compression. A case report
165
Understanding mental state from the eyes in patients with malignant brain glioma. A pilot study
166
SPINAL CORD METASTASES AS CLINICAL ONSET OF A SMARCA4-DEFICIENT UNDIFFERENTIATED TUMOR DIAGNOSED AT AUTOPSY
169
A RARE CLUE: CAVERNOUS SINUS SYNDROME AS THE FIRST SIGN OF STAGE IV DIFFUSE LARGE B-CELL LYMPHOMA
170
Neurological adverse events of Immune checkpoint inhibitor: ten-years experience at the University Hospital of Siena
NEUROPATIE 1
16
497
Efficacy, Safety, and Tolerability of Efgartigimod PH20 Subcutaneous in Patients With Chronic Inflammatory Demyelinating Polyneuropathy: Results From the ADHERE Trial
499
Gait Analysis in chronic inflammatory demyelinating polyradiculoneuropathy: a valuable tool in clinical practice
500
Diagnostic role of Magnetic Resonance Imaging in Hyperactive dysfunction syndromes: a specialist-based questionnaire
501
Polyneuropathy in wild-type transthyretin amyloidosis
502
Rituximab therapy and neurophysiological outcomes in drug-resistant inflammatory polyneuropathies
503
Transthyretin Amyloid Deposition in the Ligamentum Flavum in an Italian Cohort of Patients with Lumbar Spinal Stenosis
504
PERIPHERAL AND CENTRAL NERVOUS SYSTEM DEMYELINATION INVOLVING BILATERAL CORTICOSPINAL TRACTS: A CASE REPORT
506
A rare case of POEMS syndrome with clinical acute progression of sensory-motor demyelinating neuropathy.
507
When We See What We Expect: A Clinical and Electrodiagnostic Dilemma Case Report
509
MILLER-FISHER SYNDROME WITH PUPILLARY INVOLVEMENT
510
Lack of sensitivity of radionuclide bone scan for the diagnosis of cardiac amyloidosis related to c.250T>C Phe64Leu mutation: a case report
511
Bradycardia as initial manifestation for Guillain BarrCB) syndrome following chickenpox: a case report.
512
When you hear hoofbeats think of horses, but sometimes itCb,b"s zebra: a case of anti-neurofascin186-related neuropathy mimicking Miller-Fisher syndrome."
513
Broadening the clinical spectrum of MME related neuropathies
514
COVID-19 pandemic and emergency department visits for idiopathic facial nerve palsy: an interrupted time-series analysis
515
Chronic ataxic neuropathy with disialosyl antibodies: different clinical features and therapy response
NEUROPATIE 2
17
798
Chronic ataxic neuropathy with disialosyl antibodies: the challenge of therapy.
799
Early respiratory failure as acute onset of Myasthenia Gravis - Guillain-BarrCB) Overlap Syndrome.
800
Anti-Hu and anti-CV2 antineuronal antibodies neuropathy as clinical onset of small cell lung cancer
801
A Novel GBF1-Mutation in Charcot-Marie-Tooth disease Type 2GG: Insights from Familial Analysis
802
ATYPICAL FEATURES IN CANVAS (CEREBELLAR ATAXIA, SENSORY NEUROPATHY, VESTIBULAR AREFLEXIA SYNDROME): A CLINICAL AND GENETIC STUDY OF TWO CASES
803
Charcot-Marie-Tooth Disease Overlapping Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the importance of a correct neurophysiological diagnostic workup
804
A case of Guillain Barre' syndrome with hyperreflexia and bilateral facial palsy manifesting during Graves disease related thyrotoxicosis
805
An unusual case of bilateral radiculopathy with cranial nerve involvement: unveiling the mysteries of an immune-mediated etiology
806
Spinal cord syndrome in young individuals: uncovering the risks of nitrous oxide abuse.
807
Acute Inflammatory Demyelinating Polyradiculoneuropathy versus Viral Radiculitis: A Case Report
810
Bilateral Neuralgic Amyotrophy in HIV positive patient: a case report
811
CMAP Instability in F Response as a Diagnostic Clue for Neuromuscular Junction Disorders: A Case Report.
812
A case of Relapse of Multifocal Chronic Inflammatory Demyelinating Polyneuropathy during SARS-CoV-2 infection.
813
Charcot-Marie-Tooth Disease Type 4C Associated with SH3TC2 Mutation: A Case Report
814
Acute inflammatory demyelinating polyradiculoneuropathy unveiling systemic lupus erythematosus: causality or casuality?
816
Clinical and Diagnostic Insights into Hirayama Disease: A Case Report of a Young Female Patient
817
Ulnar neuropathy at the wrist (UNW). Retrospective clinical and electrophysiological study of 180 consecutive cases
RIABILITAZIONE NEUROLOGICA E NEUROTRAUMATOLOGIA
11
787
Indwelling urinary catheter and post-stroke rehabilitation: a couple to avoid
788
Effects of physical activity on neuroinflammation and motor function in patients with parkinson's disease: a cross-sectional study
789
The language of gait: interpreting emotional states through gait features
790
Reduction of Pain in Spasticity Patients NaCB/ve and Non-NaCB/ve to OnabotulinumtoxinA Treatment: Results from the ASPIRE Study
791
Pain Relief After Treatment With OnabotulinumtoxinA in Patients With Spasticity: Insights From the ASPIRE Study
792
USE OF BLOOD PATCH IN SPONTANEOUS INTRACRANIAL HYPOTENSION WITH ATYPICAL SYMPTOMS
793
Psychological and neurological status in patients with Spinal Cord Injury: emotional challenges during psychological treatment
794
Cranial nerve deficits predict pharyngeal phase swallowing impairment in patients with neurogenic dysphagia: a cross-sectional study
795
Enhancing collaboration between multiple sclerosis centers and rehabilitation facilities: the StayHome - ReHub initiative
796
Amantadine, selegiline and no pharmacological therapy in disorders of consciousness: comparing therapies effect on clinical outcome
797
Evaluation of the results of individualized rehabilitation programs in patients suffering from post-stroke depression at the U.O.S. STROKE UNIT Teramo (dependent on the Teramo Neurology Unit)
SCLEROSI MULTIPLA 1
19
45
Nonrelapsing secondary progressive multiple sclerosis: a challenging definition. A study of the Italian MS Register
46
Cognitive impairment and serum Neurofilament level predict disease progression in pediatric multiple sclerosis
47
Efficacy and safety of ocrelizumab in a four-year follow-up cohort of RR-MS patients
48
A 5-year population based study on ocrelizumab within different treatment strategies for multiple sclerosis
49
Secondary autoimmune diseases in patients with multiple sclerosis treated with autologous hematopoietic stem cell trasplantation.
50
Real-world comparison of Rituximab and Ocrelizumab effectiveness in Multiple Sclerosis: a multicenter study
51
Multiple Sclerosis course from onset to secondary progression: a 30-years follow-up Italian register study
52
Apolipoprotein E4 allele is associated with disability accrual as relapse associated worsening in patients with relapsing Multiple Sclerosis
53
Psychiatric onset in a MS cohort: impact on diagnosis, follow-up and prognosis. Results from a single center.
54
The risk of disease progression in absence of any clinical and radiological disease activity in natalizumab-treated patients with Multiple Sclerosis is mainly predicted by baseline EDSS score.
55
Effectiveness and safety profile of switching from Natalizumab to Ofatumumab in relapsing-MS: a multicentre real-world study
56
Comparative Analysis of Ocrelizumab and Siponimod in Elderly Patients with Multiple Sclerosis: A Real-world Study Emphasizing Similar Treatment Outcomes
57
Predictors of suboptimal response to Cladribine in a real-world setting: an Italian Multicentre Study
58
Reduced duration of breastfeeding is associated with an increased risk of pediatric onset multiple sclerosis (POMS): the PEDIGREE study
59
Cognitive Phenotypes in Multiple Sclerosis : a real world experience!
60
Validation of a unified definition of progression independent of relapse activity in relapsing multiple sclerosis
61
Managing Highly Active MS: Early Intervention with Anti-CD20 Therapies
62
It's time to talk about "door-to-needle" for Multiple Sclerosis: the role of Natalizumab and the bridge therapy
64
"Immunological dynamics in pregnancy and postpartum among women with Multiple Sclerosis: Preliminary insights from the BABIES study"
SCLEROSI MULTIPLA 2
20
65
Real-world experience of multiple sclerosis patients treated with cladribine
66
Brain gadolinium deposition in patients with MS receiving Natalizumab for extended periods
67
A propensity-matched comparison of disease activity and disability worsening in patients with multiple sclerosis treated with cladribine tablets or fingolimod
68
FOCUSING ON MYTHOCONDRIAL DYSFUNCTION IN MULTIPLE SCLEROSIS: THE ROLE OF GDF-15 AND FGF-21 AS PROGNOSTIC BIOMARKERS.
69
A multicenter observational study in a real-life cohort of naCB/ve patients treated with cladribine
70
Mapping the road ahead: spinal cord versus brain imaging biomarkers of disease trajectory in multiple sclerosis by combined 7T and 3T MRI
71
Assessment of the long-term temporal trend of immunoglobulin levels, lymphocyte subsets, and infection risk in a multiple sclerosis cohort treated with ocrelizumab: a single center experience
72
Mapping the molecular pathways of Multiple Sclerosis: A meta-analysis of gene expression studies of white matter pathology
73
Subjective cognitive impairment independent from objective disability and affective disorders: a novel aspect of cognitive phenotyping in multiple sclerosis
74
Kappa index and long-term prognosis in Multiple Sclerosis: is it useful?
75
Clinical profile and treatment outcome in MOGAD: a single centre case series study
76
Long-term changes of the peripheral immune repertoire after switching from sequestering disease-modifying treatments in Multiple Sclerosis
77
Association of Viral Infections with Human Leukocyte Antigen-DRB1 in Pediatric Multiple Sclerosis (Pedigree Study Group)
78
Multi-Omics Integration Strategies To Investigate Pediatric Multiple Sclerosis (Pedigree Study Group)
79
Epigenetics in pediatric multiple sclerosis: the PEDIGREE study
80
Usefulness of a commercial wearable device in predicting the success of intensive rehabilitation in progressive multiple sclerosis
81
Cardiorespiratory fitness moderates the association between cervical cord atrophy and disability in MS patients
82
Longitudinal Effects of Vascular Comorbidities on Multiple Sclerosis Disability Progression: Relationships with Brain Atrophy and Frailty. An 8-Year Follow-Up Study.
83
PROGRESSION INDEPENDENT OF RELAPSE AND MAGNETIC RESONANCE ACTIVITY (PIRMA) IN EARLY MULTIPLE SCLEROSIS. AN OBSERVATIONAL RETROSPECTIVE MONOCENTRIC STUDY
84
Ocrelizumab and family planning: a multi-channel approach to enhance real world insights through improved reporting
SCLEROSI MULTIPLA 3
20
384
sTREM2 and Neurogranin as early Multiple Sclerosis biomarkers in cerebrospinal fluid: a monocentric experience
385
Cytomegalovirus specific T-cell response in people with multiple sclerosis under different disease-modifying therapies
386
MS as a gendered disease: effect of sex on EDSS and robotic patterns in a cohort of patients with mild and moderate MS and a balance disorder
387
Dysphagia Assessment in Patients with Multiple Sclerosis and Its Impact on Disability Evaluation
388
Tango classes in people with Multiple Sclerosis (PwMS): impact on motor and non-motor functions
389
High adherence to the Mediterranean diet influences progressive Multiple Sclerosis course
390
Clinical, motor and Cognitive Differences in Late-Onset versus Adult-Onset Multiple Sclerosis: A Comparative Study
391
Treatment discontinuation in older patients with multiple sclerosis
392
Impact of Cladribine on cognitive functions in a real life cohort of patients with Multiple Sclerosis
393
Exploring the influence of prior disease activity in OCT dynamics after treatment onset
394
Safety assessment of switching from fingolimod to siponimod in people with Secondary Progressive Multiple Sclerosis
395
Relapse-Associated Worsening and Progression-Independent Relapse Activity in Ozanimod-Treated Participants With Relapsing Multiple Sclerosis From the RADIANCE and DAYBREAK Trials
396
Real-world experience of secondary progressive multiple sclerosis patients treated with siponimod
397
Prognostic factors in adult and pediatric onset multiple sclerosis: a systematic literature review
398
Evaluation of cladribine treatment in the Italian Multiple Sclerosis Register: treatment sequencing and effectiveness over time
399
Brief International Cognitive Assessment for MS (BICAMS) and NEDA maintenance in MS patients: a 2-years follow-up longitudinal study
400
Long-term prognostic value of early NEDA-3 vs NEDA-4 status in relapsing-remitting multiple sclerosis
401
GENETIC COLOCALIZATION BETWEEN MULTIPLE SCLEROSIS AND RELATED COMORBIDITIES
403
Epigenetic modifications induced by Ocrelizumab treatment
404
From Precision Medicine to Gender-Based Medicine: A Proteomic Analysis of Whole Saliva in Male and Female Multiple Sclerosis Patients and Healthy Controls.
SCLEROSI MULTIPLA 4
20
405
Total and cell-specific extracellular vesicles correlate with disease activity in people with Multiple Sclerosis
406
CD20 T lymphocytes in multiple sclerosis: impact on neuropsychological findings
407
Confirmed disability accrual in progressive multiple sclerosis patients treated with anti-CD20 drugs. EDSS vs EDSS-plus as outcome measure
408
Ocrelizumab and ofatumumab comparison: an Italian realCb,Bworld propensity score matched study"
409
Pediatric onset multiple sclerosis and primary headaches: is there a link?
410
Common Signs of Early Progression: Insights from the ITASIA study
411
Characteristics of Siponimod-Treated SPMS Patients in Italy: Real-World Evidence from the ITASIA Study
412
Immersive Virtual Reality and Multiple Sclerosis: Potential in Cognitive Stimulation
413
Stability of cognitive performance in treated relapsing multiple sclerosis
414
BDNF and hippocampal volume loss trajectories in early RR multiple sclerosis
415
Real-world effectiveness and safety of a third and further courses of Cladribine tablets in Relapsing Multiple Sclerosis: a short term follow-upCB from two large Italian centers
416
Saccadic Eye Movements and fatigue in newly diagnosed Multiple Sclerosis patients
418
Short-interval intracortical inhibition correlates with abnormalities of gait in early non-disabled multiple sclerosis patients.
419
Genetic risk factors for pediatricCb,b onset multiple sclerosis in the Italian population"
420
Genetic risk factors associated to incomplete recovery after first relapse in multiple sclerosis
421
Use of unprescribed cannabis in MS patients in Lombardy-Italy: safety and potential benefit
422
BTK inhibitors modulate remyelination in Multiple Sclerosis
423
Longer-term Safety and Efficacy of Ofatumumab in People with Relapsing Multiple Sclerosis for Up to 6 Years
424
Longer-term (Up to 6 Years) Efficacy of Ofatumumab in People with Recently Diagnosed and Treatment-naive Relapsing Multiple Sclerosis
425
The Cb,K mirrorC"b,b" pattern in the diagnostic work-up after the first demyelinating event can be associated with multiple sclerosis"
SCLEROSI MULTIPLA 5
21
426
Artificial Intelligence analysis of pain detected by wearable sensors in multiple sclerosis patients
427
The effect of premedication on Ofatumumab: a real-world single centre experience
428
Cytokine Phenotype of Patients with Multiple Sclerosis: Towards Precision Medicine
429
Maternal and Fetal Outcomes of Dimethyl Fumarate Exposure During Pregnancy and Breastfeeding in Relapsing Remitting Multiple Sclerosis
430
Cumulative Pregnancy Outcomes in Patients With Multiple Sclerosis Following Maternal Exposure to Ofatumumab: Results From the Novartis Safety Database
431
Real-World Efficacy of Cladribine Tablets in Relapsing-Remitting Multiple Sclerosis: Insights from a Monocentric Study
432
Iron rim lesions in newly diagnosed highly active Multiple Sclerosis patients: correlation with clinical and radiological measures.
433
Central Vein Sign analysis in confluent multiple sclerosis lesions separated with an automated algorithm
434
Opportunistic varicella zoster virus infection among patients with multiple sclerosis and association with disease modifying treatments: a monocentric study
435
Risk of HBV reactivation and loss of anti-HBc in anti-CD20 treated multiple sclerosis patients: a six-year observational cohort study
436
Cost-Consequences of Oral Cladribine for the Treatment of Highly Active Relapsing-Remitting Multiple Sclerosis in Italy
437
S1P severe lymphopenia Cb,b A Multicenter Study in Real World "
438
Safety and Efficacy of Frexalimab in the Treatment of Relapsing Multiple Sclerosis: 18-month Results from the Phase 2 Open-Label Extension
439
Real-World Effectiveness and safety of Ofatumumab in people with Multiple Sclerosis: data from a multi-center Italian 12-months follow-up study
440
Evaluating the Impact of Transcranial Alternating Current Stimulation (tACS) on Cognitive Impairemnt in People Multiple Sclerosis: A Neurophysiological and Clinical Assessment
441
ACINETOBACTER AND MS: A POSSIBLE BIOMARKER OF NEUROINFLAMMATION
442
Optical Coherence Tomography Advanced Parameters in Patients with Multiple Sclerosis: Ophthalmological and Neurological Assessments
443
Normative values of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) in an Italian young adolescent population: the influence of age, gender, and education
444
Risk of infections and ocrelizumab in the treatment of multiple sclerosis: a retrospective monocentric study
445
Fist-Palm Test (FiPaT): a novel bedside test to identify preclinical cognitive impairment in Multiple Sclerosis?
446
Effect of Ocrelizumab on specific intracellular signaling pathways modulating Vascular Endothelial Growth Factor (VEGF) Protein Expression in Relapsing Multiple Sclerosis Patients
SCLEROSI MULTIPLA 6
19
720
Seroprevalence of TORCH in women with Multiple Sclerosis of childbearing age: a monocentric study
721
Sensitivity and specificity of k-index cut off in Multiple Sclerosis: a monocentric study.
722
Your MS Questionnaire: A New Digital Tool for Enhancing Nursing Care in Real-World Settings of Multiple Sclerosis
723
Safety, efficacy, and tolerability of Siponimod: Our Experience
724
Sexual Dysfunction in Multiple Sclerosis: Unmet Needs and the Nursing Perspective
725
Exploring associations between Brain MRI and mood symptoms in multiple sclerosis
727
Real-world experience in SassariCb,b"s Multiple Sclerosis Center using Siponimod in patients with secondary progressive multiple sclerosis."
728
Observational, prospective, cohort study on a population of MS patients in the transitional phase: the experience of the Fidenza MS Centre
729
Siponimod modulates functional brain connectivity in patients with secondary progressive multiple sclerosis
730
Reshape MS Care in nursing practice: insights from an integrative review and a consensus paper
731
Efficacy and Safety of Tolebrutinib Versus Placebo in Non-Relapsing Secondary Progressive Multiple Sclerosis: Results from the Phase 3 HERCULES Trial
732
Epigenetic modifications induced by Ocrelizumab treatment
733
Exploring miRNAsCb,b" based modeling approach for predicting PIRA in Multiple Sclerosis: A Comprehensive Analysis"
734
Clinical and radiological features in Neuromyelitis Optica Spectrum Disorder (NMOSD) in a Demyelinating Disorder Centre in Italy.
735
Efficacy and Safety of Tolebrutinib Versus Teriflunomide in Relapsing Multiple Sclerosis: Results from the Phase 3 GEMINI 1 and 2 Trials
736
Phase Angle and Ketogenic Diet: Correlation with Epworth Sleepiness Scale, Fatigue Severity Scale, and Pittsburgh Sleep Quality Index in patients with Multiple Sclerosis.
737
Evaluating the Combined Effects of the "Exopulse Mollii Suit" and Fampridine on Spasticity, Fatigue and Quality of Life in Patients with Multiple Sclerosis
738
Headache and Multiple Sclerosis: an observational study in a large centre in central Italy
739
Switching from intravenous to subcutaneous natalizumab in multiple sclerosis: the patientCb,b"s perspective"
SCLEROSI MULTIPLA 7
21
740
Effectiveness of ocrelizumab treatment in patients with relapsing-remitting multiple sclerosis on No Evidence of Disease Activity (NEDA-plus): the MUSPO cohort Italian study
741
Clinical features of patients with Pediatric-Onset Multiple Sclerosis in a large Centre of Central Italy
742
Acute Myelopathy as a Presenting Symptom of Neurosarcoidosis: A Differential Diagnosis Challenge
743
Pediatric Balò disease with optic neuritis onset and dramatic sensitivity to plasmapheresis
744
Siponimod Following Alemtuzumab in Secondary Progressive Multiple Sclerosis: Investigating Sequential Therapy - A Case Series
745
RELAPSES AND STRESSORS IN LEUKOENCEPHALOPATHY WITH VANISHING WHITE MATTER SYNDROME. TWO CASE REPORTS.
746
Delayed MRI findings in CLIPPERS with comorbidities: a case report highlighting diagnostic challenges
747
Latent tuberculosis an P. jirovecii positivity in a patient with neuromyelitis optica during eculizumab treatment: a case report
748
Multiple Sclerosis and Fahr's disease: Causal or determined association?
749
Biological Agents Combination in Relapsing Remitting Multiple Sclerosis and Alopecia Areata Overlap Syndrome: a synergic action on different molecular pathways?
750
Rebound of disease activity following unscheduled discontinuation of dimethyl fumarate in relapsing-remitting Multiple Sclerosis: a description of two cases and review of scientific literature
751
Severe Neutropenia Occurring During Ofatumumab Therapy: a case report
752
Expanding the Clinical Spectrum of MOGAD: Acute Hemorrhagic Leucoencephalitis as a possible new clinical manifestation
753
Reintroduction of a CD20 depleting drug after Ocrelizumab-induced severe neutropenia: a case report.
754
A case of neutropenia and biclonal gammopathy in a patient with multiple sclerosis: alemtuzumab, cytomegalovirus and acyclovir. One culprit or several?
755
A challenging therapeutic shift in a NMOSD patient
756
Management of a patient with Multiple Sclerosis and Common Variable Immunodeficiency
757
Persistent SARS-CoV-2 Pneumonia in Multiple Sclerosis patients treated with Anti-CD20 Monoclonal Antibodies: a diagnostic challenged by negative nasopharyngeal RT-PCR
758
PRODROMAL SYMPTOMS AS PREDICTORS OF MULTIPLE SCLEROSIS SEVERITY AT ONSET AND DETERMINANTS OF EARLY HIGH-EFFICACY TREATMENT SELECTION
759
ECULIZUMAB AS RESCUE THERAPY FOR SEVERE ACUTE RELAPSE OF ANTI-AQUAPORINA4 (AQP4) ANTIBODY POSITIVE (AB+) NEUROMEYLITIS OPTICA SPECTRUM DISORDERS (NMOSD): A CASE REPORT
760
NAION-like onest in myelin oligodendrocyte glycoprotein antibody-associated optic neuritis: a MOGAD atypical presentation.
SCLEROSI MULTIPLA 8
19
761
SM Mimics in pregnancy: A Case Report of Susac Syndrome
762
Inebilizumab treatment after Rituximab failure in NMOSD: first real-world Italian experience
763
Safety and efficacy of Ustekinumab in preventing new relapses in a patient with multiple sclerosis and Crohn's disease: a first time case report
764
Safety and efficacy of eculizumab in a patient affected by NMOSD AQP4+, ankylosing spondylitis and ulcerative colitis.
765
Acute Promyelocitic Leukemia with PLZF-RARCB1 variant fusion protein arising after ofatumumab treatment in a patient with Multiple Sclerosis.
766
Siponimod and Epilepsy: a possible association? A case series
767
A case report of double-negative NMOSD treated with Satralizumab
768
Atypical Case of Recurrent Transverse Myelitis and Polyradiculopathy with anti-MOG IgG positivity
769
Demyelinating lesions after cerebral radiotherapy: a case report
770
"Peppering the pons" : a case report of Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS)"
771
Enterovirus Meningitis During Natalizumab Treatment: A Case Report
772
A case of CLIPPERS: a four-year follow-up
773
Efficacy and safety of Ofatumumab for the treatment of Relapsing Multiple Sclerosis: a single-centre real-life experience from San Raffaele Hospital.
774
Safe and effective use of ofatumumab in a patient failing rituximab treatment for a diagnostically challenging case of inflammatory demyelination
776
Immune-checkpoint inhibitors induced acute cerebellitis
777
MOGAD Encephalomyelitis mimicking an Infectious Disease: A Case Report.
778
Idiopathic intracranial hypertension as first clinical manifestations of multiple sclerosis: the role of early diagnosis
780
An unidentified case of leukoencephalopathy: investigating a potential novel immunomediated entity
781
Gait apraxia and cognitive impairment in Multiple Sclerosis patients
SISTEMA NERVOSO VEGETATIVO E SONNO
11
171
Insular and limbic abnormal functional connectivity in CB1 band in early-stage ParkinsonCb,b"s disease patients with autonomic dysfunction"
172
Painful small fiber neuropathy: a novel mutation in the SCN10A gene
175
Insomnia as Early Indicator of Neurocognitive Disorders
176
Bruxism and non-functional jaw muscular activity in the Disorders of Consciusness
177
Are the AASM scoring rules fitting for the sleep of patients with chronic Disorders of Consciousness?
178
Symptom and CPAP effect on OSA parameters at follow-up visits: the OSAREDS study data
179
Obstructive Sleep Apnea before and after CPAP titration: can real-life data detect gender differences?
180
Clinical Practice and actigraphic findings of Daridorexant in Chronic Insomnia
181
Preliminary observational multicentric STUDY of the efficacy of a nutraceutical based on Hawthorn, Griffonia and Saffron (NATACALMCB.) in patients suffering from mild to moderate anxiety disorder or insomnia attending a neurology clinic
182
Sleep Hypermotor Epilepsy vs NREM parasomnias: a challenging case report
183